BioLineRx’s (BLRX) “Hold” Rating Reiterated at Jones Trading

Jones Trading reissued their hold rating on shares of BioLineRx (NASDAQ:BLRX) in a research note released on Wednesday morning, Marketbeat reports.

A number of other research analysts also recently weighed in on BLRX. HC Wainwright upped their price target on BioLineRx from $9.00 to $26.00 and gave the stock a “buy” rating in a research note on Monday, March 31st. StockNews.com lowered BioLineRx from a “hold” rating to a “sell” rating in a research report on Tuesday, March 18th.

BioLineRx Trading Down 9.9 %

BLRX opened at $2.65 on Wednesday. The company has a fifty day moving average price of $3.40 and a two-hundred day moving average price of $10.36. BioLineRx has a 1-year low of $2.58 and a 1-year high of $35.60. The company has a market cap of $8.82 million, a P/E ratio of -0.30 and a beta of 1.39. The company has a current ratio of 1.52, a quick ratio of 1.37 and a debt-to-equity ratio of 2.11.

Institutional Investors Weigh In On BioLineRx

An institutional investor recently bought a new position in BioLineRx stock. Highbridge Capital Management LLC purchased a new stake in shares of BioLineRx Ltd. (NASDAQ:BLRX) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned about 50.50% of BioLineRx as of its most recent filing with the SEC. Hedge funds and other institutional investors own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.